Immunitrack is very pleased to announce that Karin Absalonsen has taken on the role of chairman of the board
Having previously served as a lawyer for Immunitrack, Karin Absalonsen has a first-hand understanding of the company’s mindset and goals. She has witnessed Immunitrack grow from a very small startup with many aspirations, to its current team of 11 full-time employees with collaborations with multiple research centers and biotech companies within Europe and the US.
“It is a natural step for Immunitrack to onboard Karin as our chairman. This move will give Immunitrack further structure and will help to consolidate the decision-making process with Immunitrack’s ambition to be a global partner in R&D within the fields of immuno-oncology, infectious disease and drug safety”, said Immunitrack’s CEO Stephan Thorgrimsen about the news.
Karin Absalonsen is a former lawyer and started her legal carrier at Kromann & Reumert Law Firm. She was a partner at Nyborg & Rørdam Law Firm for 17 years until June 2021, specialising in corporate law and mergers and acquisitions.
As a lawyer, Karin focused on assisting founders, management and investors in building and developing successful private life science, IT and climate innovation companies. She has also been involved in numerous Danish and international life science deals, including early stage academic spinouts, industry spin-offs, seed/venture capital financing, trade sales, bridge financing, acquisitions, and others. Karin recently left the legal profession to work full time in the life science business. Karin is a partner and co-founder of Hannibal Innovation, a newly established life science accelerator that transitions important science and technology into investable growth companies.
Speaking about her new role as chairman, Karin Absalonsen says: “Immunitrack is a very promising company with a huge potential that is backed up by a long-term and committed investor, with a strong team of dedicated and highly skilled employees. I have followed Immunitrack since its inception and I am very proud of the way that CEO Stephan Thorgrimsen and CSO Sune Justesen have developed the business. They have built an impressive and very solid customer base that includes some of the biggest pharma and biotech companies worldwide within immuno-oncology and vaccine development. With the development of Immunitrack’s unique AI-based PrDx software programme platform that provides researchers with a better tool for assessing epitope immunogenicity, we will be able to address several new markets and offer cost reductions that will ultimately benefit patients. I am really looking forward to be a part of the further development of the company”.